Coya Therapeutics, Inc. announced the acceptance and presentation of a poster at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting on October 4th, 2023. The experimental data generated in samples from ALS patients highlight the role of M1 pro-inflammatory monocytes and macrophages in reducing the immunomodulatory anti-inflammatory function of Tregs. Also documented is the significant effect of combination therapies that both enhance Treg function and suppress M1 activated macrophages and monocytes resulting in the reduction of pro-inflammatory cytokines known to be involved in inflammatory response and tissue damage.

Results of this study reinforce the potential of COYA 302 that may address the complex pathophysiology and multiple pathways involved in the progression and severity of ALS. Details of the poster presentation at the NEALS Annual Meeting are as follows: Date: October 5th, 2023 Title: Monocytes/Macrophages Impair Regulatory T-Lymphocyte Suppressive Function Poster Number: 132.